Cryoport price target raised to $22 from $12.50 at Roth Capital. Roth Capital analyst Richard Baldry reiterated a Buy rating on Cryoport (CYRX) and raised his price target to $22 from $12.50 after the EMA this morning recommended “marketing authorizations” for Gilead’s (GILD) Yescarta and Novartis’ (NVS) Kymriah, therapies developed by two of Cryoport’s clients. In a research note to investors, Baldry said he believes the two approvals roughly double the addressable market for the therapies and offer upside potential to 2019 forecasts and sees further commercial approvals as likely.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.